Motley Fool’s “King Kong for Weight Loss”: A Real Drug, Wrapped in a Fake Deadline

The Hook

“Scientists and doctors are calling it the ‘King Kong for weight loss,’ because they’ve never seen a drug like it before. It has triple the biological impact of Ozempic and registered double the weight loss results.”

That’s the opening frame of the Motley Fool’s AI Health Portfolio pitch, a $1,299-a-year letter with no refunds, and the urgency mechanism is a countdown: buy before October 29. The ad leans on two of the most reliable triggers in financial marketing at once, a monster-of-a-drug superlative and a ticking clock. The implication is that something is about to happen, and that readers who wait will miss the window.

The drug is real. The deadline is softer than the ad suggests.

The Big Claim

The marquee “King Kong” is retatrutide, Eli Lilly’s once-weekly triple hormone receptor agonist. The pitch claims it delivers “double the weight loss results” of Ozempic and a “triple” biological mechanism. The secondary claim, the one the Fool actually spreads across five additional stocks, is that GLP-1 medicines are about to go from injections to pills, and that “this single shift is about to redraw the entire playing field.”

So there are really two pitches here. One is a specific drug, retatrutide, which belongs to a $1.1 trillion company and is not a secret by any stretch. The other is a basket of five names across the obesity complex, ranging from a profitable, fast-growing Danish biotech to a $39 million microcap. The “buy before October 29” framing suggests a hard catalyst, but the StockGumshoe teardown could not pin the ad’s urgency to any single scheduled event. That’s the first thing to understand: the countdown is a conversion mechanism, not a calendar.

The Mechanism

Retatrutide’s mechanism is genuinely interesting, so it’s worth explaining. Existing GLP-1 drugs like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) hit one or two receptors. Retatrutide hits three: GLP-1, GIP, and glucagon. That third receptor is the differentiator, because glucagon signaling raises resting energy expenditure. The theory is that you don’t just suppress appetite; you also burn more. The Phase 3 data supports the hype to a degree that is honestly surprising: in the TRIUMPH-4 trial, participants on the 12 mg dose lost an average of 28.7% of body weight (71.2 pounds) over 68 weeks, and nearly 59% achieved at least 25% weight loss. The related TRIUMPH-1 readout showed 28.3% at 80 weeks, rising to 30.3% in an extension. Those numbers approach bariatric surgery territory, which no prior GLP-1 has done.

The pill-shift claim is also real. Oral GLP-1s are in development at multiple firms, and a once-daily pill meaningfully changes the market for people who won’t inject. But this is a competitive field, not a single-winner field. Novo Nordisk has an oral semaglutide, Lilly has orforglipron, and Viking has VK2735. The Fool’s framing that “a pill redraws the playing field” is correct as a trend and useless as a stock-picking edge, because the playing field is crowded.

Then there are the five non-Lilly picks, and they could not be more different from one another:

• Ascendis Pharma (ASND) is the strongest fundamental story of the bunch. Its TransCon semaglutide is dosed once a month, not once a week, and Ascendis took back the rights from Novo Nordisk. Q2 product revenue grew 105% year over year to roughly 315 million euros. This is a real, revenue-generating growth biotech, not a lottery ticket.

• Viking Therapeutics (VKTX) is the most direct “oral GLP-1” bet, with VK2735 in trials plus an amylin asset, but it is pre-revenue. The entire thesis is clinical progress, and the stock is a binary-news machine.

• Hims & Hers Health (HIMS) is the compounded-GLP-1 play. It sells telehealth plus compounded semaglutide, which is a different regulatory animal than branded drugs. When the FDA moves semaglutide off the shortage list, compounded supply is supposed to wind down. That’s a real overhang the promo doesn’t dwell on.

• Scholar Rock (SRRK) is the odd one out. Its lead asset, apitegromab, is a muscle-preservation drug for spinal muscular atrophy, not a weight-loss drug. The Fool’s angle is that muscle-preserving obesity medicine is the next frontier, which is a legitimate but thin tie to a “weight loss” portfolio.

• Veru (VERU) is a $39 million microcap. It has an oral GLP-1 candidate in early stages. This is a high-variance, single-digit stock that carries far more binary risk than the others.

So the mechanism is real, but the portfolio is not one coherent bet. It’s the whole obesity complex, from a trillion-dollar pharma giant to a microcap that could go to zero.

The Real Pick

Current prices are as of the October 27, 2026 close, pulled from Polygon.

Does the Math Check Out

Let’s put numbers next to the two big claims.

On “double the weight loss”: the comparison to Ozempic is a slight of hand. Ozempic is the diabetes dose; the obesity label is Wegovy, and semaglutide at the Wegovy dose produces roughly 15% weight loss. Retatrutide’s 28.7% is genuinely close to double that, so the claim is broadly defensible, but it’s the drug’s best Phase 3 number in a specific high-BMI osteoarthritis population, not an across-the-board result. The honest read is that retatrutide is the most effective weight-loss drug ever studied. That’s a big deal. It just isn’t a secret, and it isn’t cheap to own.

On “triple the biological impact”: that’s a marketing gloss for “hits three receptors.” The third receptor also drives the side-effect profile. In TRIUMPH-4, vomiting occurred in about 21% of patients on retatrutide versus 0% on placebo, diarrhea in roughly a third, and discontinuation rates rose with dose. A drug that powerful has tolerability tradeoffs, and the Fool’s “King Kong” framing skips that entirely.

Here’s the arithmetic problem with the pitch as a stock idea. The “King Kong” is Eli Lilly, whose market cap is already $1.14 trillion. The Fool’s own AI Health Portfolio already recommended Lilly, so the marquee tease is partly a re-pitch of a stock its subscribers already hold. The new alpha, if any, lives in the five smaller names, and those five have moved between -6.6% and +8.3% since the tease. Weighted roughly equally, that’s a low-single-digit basket gain, which is fine but hardly the “redraw the playing field” inflection the ad promises. The pill revolution may well be real, but it does not give you a time machine into which specific company wins it.

The Verdict

The thesis is real; the framing is mostly theater. Retatrutide is a genuinely important drug, and the shift to oral GLP-1s is a genuinely important trend. If you want exposure to that trend, the quality names here, Ascendis and Viking for clinical sensitivity and Lilly for the eventual winner, are worth understanding on their own merits. But do not buy any of these because of an October 29 deadline that the ad itself never actually ties to a concrete event. The right move is to treat this as a long-term, multi-year theme and buy quality on weakness, not to chase a countdown clock. For the microcaps in the basket, Veru in particular, position size is the whole ballgame.

What They Got Right

• The retatrutide enthusiasm is justified by the data. A 28.7% average weight loss is a genuine clinical breakthrough, and calling attention to it is correct.
• The “pill revolution” is real and underappreciated. Oral GLP-1s do change the addressable market, and naming it early is good analysis.
• Ascendis Pharma is a legitimate, differentiated pick. Once-monthly dosing is a real advantage, and 105% product revenue growth is a concrete, verifiable number.
• The obesity market math is enormous, hundreds of millions of potential patients globally, so the macro backdrop for the whole basket is sound.
• The Fool is transparent about its own position: it holds the marquee stock in its corporate portfolio, which is more disclosure than most newsletter pitches offer.

What They Got Wrong

• The “King Kong” is a $1.1 trillion mega-cap. Calling a drug “double Ozempic” while quietly pitching it via a company everyone already owns is the opposite of an undiscovered opportunity.
• The October 29 urgency is manufactured. The teardown could not connect the countdown to a real scheduled event, which makes the deadline a conversion tactic, not a catalyst.
• The five picks span completely different risk profiles, from a profitable Danish biotech to a $39 million microcap. Bundling them as one “play” hides how different the downside is.
• Veru’s oral GLP-1 candidate is early-stage, and the ad doesn’t surface how binary a sub-$3 microcap actually is.
• Hims & Hers’ compounded-semaglutide business carries real regulatory risk as the shortage winds down, which the “playing field” narrative glosses over.

Compliance Disclaimer

This is not financial advice. NewsletterVetter has no position in any stock mentioned, and this analysis is for educational purposes only. The Motley Fool’s own fine print on this offer notes it is a $1,299-a-year service with no refunds, which is a meaningful commitment for a pitch built around a two-day deadline. Always do your own research before acting on any promotion.

NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice.